Biologics Approved In 2012
This article was originally published in Pharmaceutical Approvals Monthly
FDA transferred review of most therapeutic biologics to the Center for Drug Evaluation & Research in 2003. The Center for Biologics Evaluation & Research continues to review other biologics, including vaccines, cellular products, antitoxins and immunoglobulins.
Allogeneic cellularized scaffold product for topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults, but not intended to provide root coverage